Advanced

LRIG1 is a prognostic biomarker in non-small cell lung cancer

Kvarnbrink, Samuel; Karlsson, Terese; Edlund, Karolina; Botling, Johan; Lindquist, David; Jirström, Karin LU ; Micke, Patrick; Henriksson, Roger; Johansson, Mikael and Hedman, Hakan (2015) In Acta Oncologica 54(8). p.1113-1119
Abstract
Background. The leucine-rich repeats and immunoglobulin-like domains (LRIG) family of transmembrane proteins are involved in the regulation of cellular signal transduction. LRIG1 is an endogenous inhibitor of receptor tyrosine kinases (RTKs) and an emerging tumor suppressor. In the lung epithelium, the expression of LRIG1 is downregulated by tobacco smoking, and further downregulated in lung squamous cell carcinoma. Material and methods. The expression of LRIG proteins were analyzed in 347 cases of non-small cell lung cancer (NSCLC) by immunohistochemistry, and LRIG1 mRNA expression was evaluated in 807 lung cancer samples in silico in the Oncomine database. Potential associations between the expression data and the clinical parameters,... (More)
Background. The leucine-rich repeats and immunoglobulin-like domains (LRIG) family of transmembrane proteins are involved in the regulation of cellular signal transduction. LRIG1 is an endogenous inhibitor of receptor tyrosine kinases (RTKs) and an emerging tumor suppressor. In the lung epithelium, the expression of LRIG1 is downregulated by tobacco smoking, and further downregulated in lung squamous cell carcinoma. Material and methods. The expression of LRIG proteins were analyzed in 347 cases of non-small cell lung cancer (NSCLC) by immunohistochemistry, and LRIG1 mRNA expression was evaluated in 807 lung cancer samples in silico in the Oncomine database. Potential associations between the expression data and the clinical parameters, including patient survival, were investigated. Results. Expression of the LRIG1 protein was found to be an independent prognostic factor in NSCLC, whereas expression of LRIG2 or LRIG3 did not correlate with patient survival. The levels of LRIG1 mRNA also correlated with the survival of NSCLC patients. Conclusion. These findings demonstrate that LRIG1 is an independent prognostic factor in patients with NSCLC that could be important in future decision-making algorithms for adjuvant lung cancer treatment. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Acta Oncologica
volume
54
issue
8
pages
1113 - 1119
publisher
Taylor & Francis
external identifiers
  • wos:000361285500004
  • scopus:84940479247
ISSN
1651-226X
DOI
10.3109/0284186X.2015.1021427
language
English
LU publication?
yes
id
76191b44-a29c-4a9d-8971-cece5f92ad79 (old id 8074158)
date added to LUP
2015-11-19 10:40:39
date last changed
2017-10-01 04:15:30
@article{76191b44-a29c-4a9d-8971-cece5f92ad79,
  abstract     = {Background. The leucine-rich repeats and immunoglobulin-like domains (LRIG) family of transmembrane proteins are involved in the regulation of cellular signal transduction. LRIG1 is an endogenous inhibitor of receptor tyrosine kinases (RTKs) and an emerging tumor suppressor. In the lung epithelium, the expression of LRIG1 is downregulated by tobacco smoking, and further downregulated in lung squamous cell carcinoma. Material and methods. The expression of LRIG proteins were analyzed in 347 cases of non-small cell lung cancer (NSCLC) by immunohistochemistry, and LRIG1 mRNA expression was evaluated in 807 lung cancer samples in silico in the Oncomine database. Potential associations between the expression data and the clinical parameters, including patient survival, were investigated. Results. Expression of the LRIG1 protein was found to be an independent prognostic factor in NSCLC, whereas expression of LRIG2 or LRIG3 did not correlate with patient survival. The levels of LRIG1 mRNA also correlated with the survival of NSCLC patients. Conclusion. These findings demonstrate that LRIG1 is an independent prognostic factor in patients with NSCLC that could be important in future decision-making algorithms for adjuvant lung cancer treatment.},
  author       = {Kvarnbrink, Samuel and Karlsson, Terese and Edlund, Karolina and Botling, Johan and Lindquist, David and Jirström, Karin and Micke, Patrick and Henriksson, Roger and Johansson, Mikael and Hedman, Hakan},
  issn         = {1651-226X},
  language     = {eng},
  number       = {8},
  pages        = {1113--1119},
  publisher    = {Taylor & Francis},
  series       = {Acta Oncologica},
  title        = {LRIG1 is a prognostic biomarker in non-small cell lung cancer},
  url          = {http://dx.doi.org/10.3109/0284186X.2015.1021427},
  volume       = {54},
  year         = {2015},
}